Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/63—Esters of sulfonic acids
  • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
  • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
  • C07C309/66—Methanesulfonates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
  • C07C309/63—Esters of sulfonic acids
  • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
  • C07C31/34—Halogenated alcohols
  • C07C31/44—Halogenated alcohols containing saturated rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
  • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
  • C07C35/04—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

• R1 is R2 is hydrogen, -PO3H2, or- -R3 wherein R3 is hydrogen,alkyl, substituted alkyl, or aryl and R4 is alkyl.
• Preferred compounds of formula 1 are when R1 is
• alkyl refers to both straight and branched chain groups. Those groups having 1 to 10 carbons are preferred.
• substituted alkyl refers to alkyl groups having one or more substituents. Preferred substituents are halogen, amino, azido, hydroxy, cyano, trialkylammonium (wherein each alkyl group has 1 to 6 carbons), alkoxy of 1 to 6 carbons, aryl and carboxy.
• aryl refers to phenyl and phenyl substituted with one, two or three substi­tuents.
• Preferred substitutents are alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, nitro, cyano, alkanoyloxy of 2 to 11 carbons, carboxy, carbamoyl and hydroxy.
• the compounds of formula 1 are antiviral agents that can be used to treat viral infection in mammalian species such as domesticated animals (e.g. , dogs, cats, horses and the like) and humans, and avian species (e.g. , chickens and turkeys).
• the compounds of formula 1 wherein R1 is are effective against one or more of the following viruses: herpes simplex virus 1 and 2, varicella-­zoster virus , murine leukemia virus and human immunodeficiency virus (HIV). They are also believed to be active against a variety of other DNA and retroviruses.
• Exemplary DNA viruses in addition to those named above include other herpes viruses (e.g.
• Epstein-Barr virus Epstein-Barr virus, pseudorabies virus, other poxviruses (e.g. monkey pox and myoma), papovaviruses (e.g. , the papilloma viruses), hepatitis B virus, and adenoviruses.
• poxviruses e.g. monkey pox and myoma
• papovaviruses e.g. , the papilloma viruses
• hepatitis B virus e.g. adenoviruses
• exemplary retroviruses in addition to those named above include those effecting man, such as human T-cell lymphotropic viruses (HTLV), and those effecting other animals, such as feline leukemia virus and equine infectious anemia virus.
• HTLV human T-cell lymphotropic viruses
• All of the other compounds of formula 1 are believed to be active against one or more of the following viruses: herpes simplex virus 1 and 2, varicella-zoster virus, cytomegalovirus, murine leukemia virus, human immunodeficiency virus and the other viruses described above.
• the compounds of this invention may be administered parenterally (for example, by intra­venous, intraperitoneal or intramuscular injection), orally or topically.
• the compounds may be administered orally or parenterally in an amount effective to treat the infection.
• the dosage will, of course, depend on the severity of the infection, but will likely be in the range of about 1.0 to 50 mg/kg of body weight.
• the desired dose may be administered several times daily at appropriate intervals.
• compositions may be applied to the infected part of the body of the patient topically as an ointment, cream, aerosol, gel, powder, lotion, suspension or solution (e.g. as in eye drops).
• concentration of the compound in the vehicle will, of course, depend on the severity of the infection, but will likely be in the range of about 0.1 to 7% by weight.
• a compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from an intermediate of formula wherein P is a protecting group such as acyl, or silyl, and X is a leaving group such as chloro, bromo, iodo or an aryl or alkyl sulfonate (e.g. , p-toluenesulfonyloxy or methanesulfonyloxy).
• acyl refers to groups R5- - wherein R5 is a lower alkyl group of 1-6 branched or straight chain carbon atoms or a phenyl group.
• sil refers to silyl protecting groups well known in the art [e.g ., t-butyldimethylsilyl, t-butyldiphenylsilyl, (triphenylmethyl)dimethyl­silyl, methyldiisopropylsilyl, or triisopropyl­silyl].
• the reaction can be run in the presence of a metal chelating agent such as 18-­crown-6 (1,4,7,10,13,16-hexaoxacyclooctadecane) or 15-crown-5 (1,4,7,10,13-pentaoxacyclopentade­cane).
• a metal chelating agent such as 18-­crown-6 (1,4,7,10,13,16-hexaoxacyclooctadecane) or 15-crown-5 (1,4,7,10,13-pentaoxacyclopentade­cane).
• the protecting group P in 4 is an acyl group
• the protecting group P can be selectively removed using, for example, catalytic sodium methoxide in methanol or methanolic ammonia.
• Subsequent removal of the O-benzyl protecting group on the purine moiety can be accomplished by treatment with aqueous alcoholic mineral acid (e.g. , aqueous methanolic hydrochloric acid), sodium in liquid ammonia, or by hydrogenolysis (e.g. , palladium hydroxide on carbon in cyclohexene and ethanol).
• aqueous alcoholic mineral acid e.g. , aqueous methanolic hydrochloric acid
• hydrogenolysis e.g. , palladium hydroxide on carbon in cyclohexene and ethanol
• the purine O-benzyl protecting group can be removed initially, followed by removal of the acyl pro­tecting group.
• the group P in compound 4 is a silyl protecting group
• removal of the P group can be accomplished using fluoride ion (e.g. , tetra­butylammonium fluoride in tetrahydrofuran).
• fluoride ion e.g. , tetra­butylammonium fluoride in tetrahydrofuran.
• the purine O-benzyl protecting group can then be removed with aqueous alcoholic mineral acid, sodium in liquid ammonia, or by hydrogenolysis.
• a compound of formula 2 can be synthesized from a compound of formula 5 , whose preparation is described in the literature (See C. J. Michejda et al. , J. Org. Chem. , 40 , 1046 (1975) and C. Beard et al. , Chem. Ber. , 95, 2535 (1962)). Heating a compound of formula 5 in vacuo according to the literature (C. Beard et al. , Chem. , Ber. , 95 , 2535 (1962); J. Safanda et al. , Coll. Czech. Chem. Communs. , 47, 2441 (1982)) affords a compound of formula 6 , having a m.p.
• the compound of formula 10 can be converted to a compound of formula 2 by methods known in the art. For example, treatment of 10 with p-toluene­sulfonyl chloride or methanesulfonyl chloride in pyridine yields a compound of formula 2 wherein X is p-toluenesulfonyloxy or methanesulfonyloxy, respectively.
• the compound of formula 2 wherein P is benzoyl and X is p-toluenesulfonyloxy has a melting point 81-82°, and its structure was con­ firmed by a single crystal X-ray analysis.
• the compound of formula 2 wherein X is p-toluene­sulfonyloxy or methanesulfonyloxy can also be prepared from a compound of formula 13 by treatment with p-toluenesulfonic acid or methane­sulfonic acid, respectively, in the presence of triethylamine, triphenylphosphine, and diethyl or diisopropyl azodicarboxylate in a solvent such a toluene, ether or dioxane.
• the compound of formula 13 can be prepared from a compound of formula 7 following the methodology used to convert compound 6 to the compound of formula 10 .
• Treatment of 7 with lithium aluminum hydride affords a compound of formula 11 .
• Protection of the hydroxyl group in 11 yields a compound of formula 12 and debenzylation gives the compound of formula 13 .
• a compound of formula 2 wherein X is chloro, bromo, or iodo can be prepared from the compound of formula 13 using triphenylphosphine, diethyl (or diisopropyl) azodicarboxylate, and a source of halide such as methyl iodide, methyl bromide, or dichloromethane according to methodology known in the art. See, for example, H. Loibner et al. Helv. Chim. Acta. 59 , 2100 (1976).
• Selective removal of the protecting group P provides a compound of formula 1 wherein R1 is and R2 is hydrogen.
• R1 is and R2 is hydrogen.
• the protecting group P in 15 is acyl
• the P group can be selectively removed using, for example, catalytic sodium methoxide in methanol.
• the protecting group P in 15 is silyl
• the protecting group can be selectively removed by treatment with fluoride ion (e.g. , tetrabutylammonium fluoride).
• Acid hydrolysis e.g. , using hot aqueous hydrochloric acid
• a compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from a compound of formula 15 .
• the chloro group can first be reduced by hydrogenation (e.g. ammonium formate and palladium on carbon in methanol or ethanol; palladium on carbon and cyclohexene in ethanol; or palladium on carbon, hydrogen and ethanol) and then the protecting group P can be removed using either catalytic sodium methoxide in methanol or methanolic ammonia when P is acyl, and fluoride ion when P is silyl.
• the acyl or silyl protecting group P can be removed first and then the chloro group can be reduced.
• this compound of formula 1 can be prepared by reacting an optionally protected compound of formula with a compound of formula 2 according to procedures analogous to those used in the preparation of a compound of formula 4 , followed by removal of the protecting groups by methods known in the art.
• An optionally protected form of compound 16 can be protected at the amino (-NH2) group by such exemplary groups as acyl, trityl, or substituted trityl.
• exemplary substituted trityl groups are 4-monomethoxytrityl and 4,4′-dimethoxy­trityl.
• a compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from a compound of formula 15 by treatment with hot methanolic ammonia according to methods known in the art (e.g. , J.C. Martin, et al. , J. Med. Chem. 28 , 358(1985)).
• the protecting group P in 15 is acyl
• treatment with hot methanolic ammonia results in substitution of the chloro group by an amino group and simultaneous removal of the acyl protecting group.
• the protecting group P is a silyl group, replacement of the chloro group by an amino group can be accomplished first, and then the protecting group P can be removed, for example, by treatment with fluoride ion.
• this compound of formula 1 can be prepared by reacting an optionally protected compound of formula with a compound of formula 2 according to pro­cedures analogous to those used in the preparation of a compound of formula 4 , followed by removal of the protecting groups by methods known in the art.
• An optionally protected form of 17 can be protected at the amino (-NH2) group by such exemplary groups as acyl, trityl or substituted trityl.
• a compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from a a com­pound of formula 1 wherein R1 is and R2 is hydrogen by methods known in the art. See, for example, J.F. Gerster, et al. , J. Amer. Chem. Soc. , 87 , 3752 (1965); K.K. Ogilvie, et al. , Can. J.. Chem. , 62, 2702 (1984); M.R. Harnden, et al. , J. Med. Chem. , 30 , 1636 (1987).
• the compound of formula 1 can be prepared by reacting a compound of formula with a compound of formula 2 according to procedures analogous to those used in the preparation of a compound of formula 4 , followed by removal of the protecting group P by methods known in the art.
• the compound of formula 18 can be prepared from the compound of formula 14 by methods known in the art. See, for example, W.A. Bowles, et al. , J. Med. Chem. , 6 , 471 (1963); M. MacCoss, et al. , Tetrahedron Lett. , 26 , 1815 (1985).
• this compound of formula 1 can be prepared by reaction of a compound of formula with a compound of formula 2 by methods analogous to those used in the preparation of a compound of formula 4 .
• the compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from a compound of formula 21 by selective removal of the P protecting group.
• the P protecting group P in 21 is acyl
• the P group can be selectively removed using, for example, catalytic sodium methoxide in methanol.
• the protecting group P in 21 is silyl
• the protecting group P can be selectively removed by treatment with fluoride ion (e.g. , tetrabutylammonium fluoride).
• Acid hydrolysis e.g. , using hot aqueous hydrochloric acid
• basic hydrolysis e.g. , aqueous methanolic sodium hydroxide
• this compound of formula 1 can be prepared by treatment of a compound of formula 1 wherein R1 is and R2 is hydrogen with adenosine deaminase according to methods known in the art (e.g. , M.J. Robins, et al. , J. Med. Chem. , 27 , 1486 (1984); K.K. Ogilvie, et al. , Can. J. Chem. , 62 , 241 (1984)).
• the compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared by reaction of a compound of formula 2 with a compound of formula by methodology analogous to that used to prepare a compound of formula 4 , and subsequent removal of the P protecting group.
• the protecting group can be removed by treatment with sodium methoxide in methanol or methanolic ammonia, or when P is a silyl group, deprotection can be accomplished with fluoride ion.
• the compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared by reaction of a compound of formula 2 with a compound of formula by methodology analogous to that used to prepare a compound of formula 4 , and subsequent removal of the P protecting group.
• the amino (-NH2) group in 23 can be protected, e.g. , with an acyl group. Removal of this protecting group can be accomplished using sodium methoxide in methanol or methanolic ammonia.
• the compound of formula 1 wherein R1 is and R2 is hydrogen can be prepared from a compound of formula (wherein P is an acyl protecting group) by methods known in the art, and subsequent removal of the P protecting group. See, for example, I. Wempner, et al. , in "Synthetic Procedures in Nucleic Acid Chemistry", Vol. 1, W. W. Zorbach and R. S. Tipson, Eds., Interscience Publishers, N.Y., p. 299, 1968; T.S. Lin, et al. , J. Med. Chem. , 26 , 1691 (1983); P. Herdewijn, et al. , J. Med. Chem. , 28, 550 (1985).
• the compound of formula 24 can be prepared by reaction of a compound of formula with a compound of formula 2 according to procedures analogous to those used in the preparation of a compound of formula 4 .
• R1 can form acid addition salts with inorganic or organic acids
• inorganic or organic acids Illustrative are the hydrohalide (e.g. , hydrochloride and hydrobromide), alkylsul­fonate, sulfate, phosphate and carboxylate salts.
• the compounds of formula 1 wherein R1 is can form basic salts with inorganic and organic bases.
• Illustrative are alkali metal salts (e.g. , sodium and potassium), alkaline earth metal salts (e.g. calcium and magnesium), ammonium and substituted ammonium salts.
• the compounds of formula 1 wherein R2 is -PO3H2 can form basic salts with inorganic and organic bases.
• Illustrative are the alkali metal salts (e.g. , sodium and potassium), alkaline earth metal salts (e.g. , calcium and magnesium), ammonium and substituted ammonium salts.
• trans isomer 10% of the trans isomer.
• the combined fractions of trans isomer were recrystallized from pentane-diisopropyl ether to give 13 g of crystals (m.p. 46-48°) consisting of 95% ( trans )-3-(phenylmethoxy)-cyclobutane­carboxylic acid and 5% ( cis )-3-(phenylmethoxy)­cyclobutanecarboxylic acid.
• Trans isomer 1HNMR (CDCl3, 400MHz) ⁇ 7.2 - 7.4 (m, 5H), 4.41 (s, 2H), 4.30 (quintet, 1H), 3.07 (m, 1H), 2.53 (m, 2H), 2.34 (m, 2H).
• Cis isomer 1HNMR (CDCl3, 400MHz) ⁇ 7.2 - 7.4 (m, 5H), 4.43 (s, 2H), 3.96 (septet, 1H), 2.64 (m, 1H), 2.50 (m, 2H), 2.29 (m, 2H).
• reaction mixture was concentrated in vacuo to an oil, absorbed onto Baker silica gel using dichloro­methane and chromatographed over 200 ml of LPS-1 silica gel, using ethyl acetate-hexane (7:3), to give 447 mg of desired product as a residue.
• HSV-1 (herpes simplex virus type 1, strain Schooler), HSV-2 (herpes simplex virus type 2, strain 186), VZV (varicella zoster virus, strain ELLEN), MuLV (murine leukemia virus, strain CAS), HIV (human immunodeficiency virus, strain HTLV-IIIB).
• HSV-1, HSV-2, and VZV antiviral assays are HSV-1, HSV-2, and VZV antiviral assays:
• Virus was adsorbed to WI-38 cell culture monolayers in 6 well culture plates (Costar, Cambridge, MA) for 1 hour prior to addition of maintenance medium containing duplicate dilutions of the test compound. Inhibition of plaque development was evaluated on fixed and stained monolayers after 4 days incubation at 37°C for HSV-1 and HSV-2 and after 6-7 days incubation at 37°C for VZV. ID50 values were determined from the drug concentration which conferred at least a 50% plaque reduction compared to virus controls.
• Suspensions of CEM cells were infected at a multiplicity of infection of 0.12 TCID50/cell with HIV (strain HTLV-III B). After adsorption for 1-2 hours at 37°C, infected cells were diluted in growth medium (RPMI 1640 containing the antibiotics penicillin plus strepto­mycin and 10% fetal calf serum) to give a final cell concentration of 1 x 104 viable cells/culture well in the presence of serial dilutions of the test compound, starting at 100 ⁇ g/ml. Triplicate samples at each drug concentration were used.
• CPE viral cytopathic effect

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (3)

Family

ID=22825237

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (2)

Citations (5)

Family Cites Families (9)

• 1989
  • 1989-06-16 US US07/367,167 patent/US5369098A/en not_active Expired - Lifetime
  • 1989-07-11 CA CA000605279A patent/CA1340496C/fr not_active Expired - Fee Related
  • 1989-07-13 DE DE68926367T patent/DE68926367T2/de not_active Expired - Fee Related
  • 1989-07-13 EP EP89307088A patent/EP0352013B1/fr not_active Expired - Lifetime
  • 1989-07-18 JP JP1187189A patent/JPH0273072A/ja active Pending

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events